Apogee Therapeutics to delist Nasdaq; trading suspended Sept. 4, 2026
Apogee Therapeutics notified Nasdaq it has consummated its merger and intends to remove all common stock from Nasdaq, requesting Nasdaq file Form 25 to delist and deregister. Trading will be suspended Sept. 4, 2026.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.